Uncategorized Archives - PTX Therapeutics

Toggle menu

HOME
ABOUT US
TECHNOLOGIES
- Our Technologies
- PIPELINE
INVESTORS
MEDIA
- Media
- Briefing recordings
CONTACT US

Category: Uncategorized

Home > Uncategorized

Prescient Therapeutics nearing a potential payday with PTX-100: Pitt Street Research

Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF)’s lead compound PTX-100 is potentially a significant future treatment for T-Cell Lymphoma, according to a research note from Pitt Street…

Uncategorized 0

November 15, 2023 AUTHOR – enouvoteam

STOCK PRICE

ASX ANNOUNCEMENTS

Tags

AusBiz Biotech Dispatch BioWorld CGT Live Global Victoria Investing Kalkine Kalkine Media Market Herald Market Open Mirage News National Tribune Pitt Street Research Port Jackson Securities Prescient Therapeutics Proactive Investors Reach Markets ShareCafe Share Cafe Small Caps Smallcaps Stockhead Switzer TechKnow Invest Roadshow The Australian The Australian Business Review The Market Herald The Sentiment Yahoo Finance

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cell therapies.

CONTACT

P: +61 3 9692 7222

F: +61 3 9077 9233

E: [email protected]

INVESTORS

This Investor Centre was built by Reach Markets.
Visit Reach Markets here

WordPress Theme built by Shufflehound.

Subscribe for updates

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Corporate provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.

Do you qualify as a Wholesale (708) investor?

Wholesale 708 Sophisticated Investors are individuals or entities who generally qualify under Sections 708(8) and s761G(7) of the Corporations Act based on the gross income and/or net assets test verified by a qualified accountant.

A gross income of $250,000 or more per annum in each of the previous two financial years; or
Net assets of at least $2.5 million; and
A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)

Category: Uncategorized

Uncategorized

Prescient Therapeutics nearing a potential payday with PTX-100: Pitt Street Research

RECENT POSTS

Prescient Therapeutics to present PTX-100 results at 5th World Congress of Cutaneous Lymphomas

Prescient Therapeutics on cusp of value creation, says Pitt Street Research

Prescient Therapeutics (ASX: PTX) advances PTX-100 to pivotal Phase 2 study

Categories